



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Regadenoson Injection Safety Data Sheet	SDS Number: SDS-000053	Page Number: Page 1 of 16
Function: Regulatory Affairs	Effective Date: February 24, 2026	Version number: 3.0

Section 1. Identification

GHS product identifier : Regadenoson Injection

Other means of identification : Not available.

Product type : Liquid.

Relevant identified uses of the substance or mixture and uses advised against

Product use : Pharmaceuticals. (For intended use only.)
Observe technical data sheet/instructions for use.
Specific Treatments: Pharmacologic stress agent.

Area of application : Professional applications.

Supplier's details : Meitheal Pharmaceuticals, Inc.
8700 W. Bryn Mawr, Suite 600S
Chicago, IL 60631

Telephone: 224-443-4617
www.meithealpharma.com

e-mail address of person responsible for this SDS : info@meithealpharma.com

Emergency telephone number (with hours of operation) : 844-824-8426 (Monday - Friday, 08:00 - 18:00 CST)

Section 2. Hazards identification

OSHA/HCS status : This material is considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200).

Classification of the substance or mixture : H320 EYE IRRITATION - Category 2B

GHS label elements

Signal word : Warning

Hazard statements : H320 - Causes eye irritation.

Precautionary statements

Prevention : P264 - Wash thoroughly after handling.

Response : P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes.
Remove contact lenses, if present and easy to do. Continue rinsing.
P337 + P313 - If eye irritation persists: Get medical advice or attention.

Storage : Not applicable.

Disposal : Not applicable.

SDS Title: Regadenoson Injection Safety Data Sheet	SDS Number: SDS-000053	Page Number: Page 2 of 16
Function: Regulatory Affairs	Effective Date: February 24, 2026	Version number: 3.0

Section 2. Hazards identification

- Hazards not otherwise classified** : None known.
- Hazards identified when used** : No known significant effects or critical hazards.

Section 3. Composition/information on ingredients

- Substance/mixture** : Mixture
- Other means of identification** : Not available.

Ingredient name	Synonyms	%	Identifiers
Water	-	≥65 - ≤85	CAS: 7732-18-5
propane-1,2-diol	Propylene Glycol	≥10 - ≤30	CAS: 57-55-6
disodium hydrogenorthophosphate	-	≥0.1 - ≤1	CAS: 7558-79-4
Phosphoric acid, monosodium salt, monohydrate	Monobasic Sodium Phosphate, monohydrate	≥0.1 - ≤1	CAS: 10049-21-5
Glycine, N,N'-1,2-ethanediylbis[N-(carboxymethyl)-, sodium salt, hydrate (1:2:2)	Edetate Disodium	≥0.1 - ≤1	CAS: 6381-92-6
regadenoson	-	≤0.1	CAS: 313348-27-5

Any concentration shown as a range is to protect confidentiality or is due to batch variation.

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified and hence require reporting in this section.

Section 4. First aid measures

Description of necessary first aid measures

- Eye contact** : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. If irritation persists, get medical attention.
- Inhalation** : Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention if adverse health effects persist or are severe. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
- Skin contact** : Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur. Wash clothing before reuse. Clean shoes thoroughly before reuse.

SDS Title: Regadenoson Injection Safety Data Sheet	SDS Number: SDS-000053	Page Number: Page 3 of 16
Function: Regulatory Affairs	Effective Date: February 24, 2026	Version number: 3.0

Section 4. First aid measures

- Ingestion** : Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

Most important symptoms/effects, acute and delayed

Potential acute health effects

- Eye contact** : Causes eye irritation.
- Inhalation** : No known significant effects or critical hazards.
- Skin contact** : No known significant effects or critical hazards.
- Ingestion** : No known significant effects or critical hazards.

Over-exposure signs/symptoms

- Eye contact** : Adverse symptoms may include the following:
irritation
watering
redness
- Inhalation** : No specific data.
- Skin contact** : No specific data.
- Ingestion** : No specific data.

Indication of immediate medical attention and special treatment needed, if necessary

- Notes to physician** : Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
- Specific treatments** : No specific treatment.
- Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.

See toxicological information (Section 11)

Section 5. Fire-fighting measures

Extinguishing media

- Suitable extinguishing media** : Use an extinguishing agent suitable for the surrounding fire.
- Unsuitable extinguishing media** : Do not use water jet.

- Specific hazards arising from the chemical** : In a fire or if heated, a pressure increase will occur and the container may burst.

SDS Title: Regadenoson Injection Safety Data Sheet	SDS Number: SDS-000053	Page Number: Page 4 of 16
Function: Regulatory Affairs	Effective Date: February 24, 2026	Version number: 3.0

Section 5. Fire-fighting measures

Hazardous thermal decomposition products

- : Decomposition products may include the following materials:
carbon dioxide
carbon monoxide

Special protective actions for fire-fighters

- : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire-fighters

- : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Section 6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

- : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Avoid breathing vapor or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.

For emergency responders

- : If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

Environmental precautions

- : Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

Methods and materials for containment and cleaning up

Small spill

- : Stop leak if without risk. Move containers from spill area. Absorb with an inert material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

Large spill

- : Stop leak if without risk. Move containers from spill area. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product. Contain and collect spillage with non-combustible, absorbent material e. g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations.

SDS Title: Regadenoson Injection Safety Data Sheet	SDS Number: SDS-000053	Page Number: Page 5 of 16
Function: Regulatory Affairs	Effective Date: February 24, 2026	Version number: 3.0

Section 7. Handling and storage

Precautions for safe handling

Protective measures

- : Put on appropriate personal protective equipment (see Section 8). Do not ingest. Avoid contact with eyes, skin and clothing. Avoid breathing vapor or mist. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.

Advice on general occupational hygiene

- : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

Conditions for safe storage, including any incompatibilities

- : Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Section 8. Exposure controls/personal protection

Control parameters

Occupational exposure limits

Ingredient name	Exposure limits
Water	None.
propane-1,2-diol	OARS WEEL (United States, 9/2024) TWA 8 hours: 10 mg/m ³ .
disodium hydrogenorthophosphate	None.
Phosphoric acid, monosodium salt, monohydrate	None.
Glycine, N,N'-1,2-ethanediylbis[N-(carboxymethyl)-, sodium salt, hydrate (1:2:2)	None.
regadenoson	None.

Biological exposure indices

None known.

Appropriate engineering controls

- : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

Environmental exposure controls

- : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Individual protection measures

SDS Title: Regadenoson Injection Safety Data Sheet	SDS Number: SDS-000053	Page Number: Page 6 of 16
Function: Regulatory Affairs	Effective Date: February 24, 2026	Version number: 3.0

Section 8. Exposure controls/personal protection

- Hygiene measures** : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
- Eye/face protection** : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.
- Skin protection**
- Hand protection** : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.
- Body protection** : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
- Other skin protection** : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
- Respiratory protection** : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Section 9. Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

Appearance

- Physical state** : Liquid. [Clear.]
- Color** : Colorless.
- Odor** : Not available.
- Odor threshold** : Not available.
- pH** : 6.3 to 7.7
- Melting point** : Not available.
- Boiling point or initial boiling point and boiling range** : Not available.
- Flash point** :

SDS Title: Regadenoson Injection Safety Data Sheet	SDS Number: SDS-000053	Page Number: Page 7 of 16
Function: Regulatory Affairs	Effective Date: February 24, 2026	Version number: 3.0

Section 9. Physical and chemical properties

Ingredient name	Closed cup			Open cup		
	°C	°F	Method	°C	°F	Method
propane-1,2-diol	99	210.2				

Evaporation rate : Not available.
Flammability : Not available.
Lower and upper explosion limit/flammability limit : Not available.
Vapor pressure :

Ingredient name	Vapor Pressure at 20°C			Vapor pressure at 50°C		
	mm Hg	kPa	Method	mm Hg	kPa	Method
Water	17.5	2.3		92.258	12.3	

Relative vapor density : Not available.
Relative density : Not available.
Density : 1.0168 to 1.023 g/cm³ [25°C (77°F)]
Solubility(ies) :

Media	Result
water	Very slightly soluble

Miscible with water : No.
Partition coefficient: n-octanol/water : Not applicable.
Auto-ignition temperature :

Ingredient name	°C	°F	Method
propane-1,2-diol	371	699.8	

Decomposition temperature : Not available.
SADT : Not available.
Viscosity : Dynamic (room temperature): Not available.
Kinematic (room temperature): Not available.
Kinematic (40°C (104°F)): Not available.

Particle characteristics
Median particle size : Not applicable.
Other information
Physical/chemical properties comments : No additional information.

SDS Title: Regadenoson Injection Safety Data Sheet	SDS Number: SDS-000053	Page Number: Page 8 of 16
Function: Regulatory Affairs	Effective Date: February 24, 2026	Version number: 3.0

Section 10. Stability and reactivity

Reactivity	: No specific test data related to reactivity available for this product or its ingredients.
Chemical stability	: The product is stable.
Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur. Under normal conditions of storage and use, hazardous polymerization will not occur.
Conditions to avoid	: No specific data.
Incompatible materials	: No specific data.
Hazardous decomposition products	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Section 11. Toxicological information

Information on toxicological effects

Acute toxicity

Product/ingredient name	Result	
propane-1,2-diol	Rat - Oral - LD50 20 g/kg Rabbit - Dermal - LD50 20800 mg/kg	<u>Toxic effects:</u> Behavioral - Ataxia Behavioral - Tetany Lung, Thorax, or Respiration - Respiratory depression
disodium hydrogenorthophosphate	Rat - Oral - LD50 17000 mg/kg Rat - Male, Female - Dermal - LD50 >2000 mg/kg	OECD [Acute Dermal Toxicity]
Glycine, N,N'-1,2-ethanediylbis[N-(carboxymethyl)-, sodium salt, hydrate (1:2:2)]	Rat - Oral - LD50 2214.37 mg/kg	

Conclusion/Summary [Product] : Not available.

Skin corrosion/irritation

Product/ingredient name	Result
disodium hydrogenorthophosphate	Rabbit - Skin - Mild irritant Duration of treatment/exposure: 24 hours Amount/concentration applied: 500 mg



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Regadenoson Injection Safety Data Sheet	SDS Number: SDS-000053	Page Number: Page 9 of 16
Function: Regulatory Affairs	Effective Date: February 24, 2026	Version number: 3.0

Section 11. Toxicological information

Conclusion/Summary [Product] : Not available.

Serious eye damage/eye irritation

Product/ingredient name

propane-1,2-diol

Result

Rabbit - Eyes - Mild irritant

Duration of treatment/exposure: 24 hours

Amount/concentration applied: 500 mg

Rabbit - Eyes - Mild irritant

Amount/concentration applied: 100 mg

disodium hydrogenorthophosphate

Rabbit - Eyes - Mild irritant

Duration of treatment/exposure: 24 hours

Amount/concentration applied: 500 mg

Conclusion/Summary [Product] : Not available.

Respiratory corrosion/irritation

Conclusion/Summary [Product] : Not available.

Respiratory or skin sensitization

Skin

Conclusion/Summary [Product] : Not available.

Respiratory

Conclusion/Summary [Product] : Not available.

Germ cell mutagenicity

Conclusion/Summary [Product] : Not available.

Carcinogenicity

Conclusion/Summary [Product] : Not available.

Reproductive toxicity

SDS Title: Regadenoson Injection Safety Data Sheet	SDS Number: SDS-000053	Page Number: Page 10 of 16
Function: Regulatory Affairs	Effective Date: February 24, 2026	Version number: 3.0

Section 11. Toxicological information

Conclusion/Summary [Product] : Not available.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Product/ingredient name

Glycine, N,N'-1,2-ethanediybis[N-(carboxymethyl)-, sodium salt, hydrate (1:2:2)

Result

SPECIFIC TARGET ORGAN TOXICITY (REPEATED EXPOSURE) (respiratory tract) (inhalation) - Category 2

Aspiration hazard

Not available.

Information on the likely routes of exposure

Routes of entry anticipated: Oral, Dermal, Inhalation, Eyes.

Potential acute health effects

Eye contact	: Causes eye irritation.
Inhalation	: No known significant effects or critical hazards.
Skin contact	: No known significant effects or critical hazards.
Ingestion	: No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact	: Adverse symptoms may include the following: irritation watering redness
Inhalation	: No specific data.
Skin contact	: No specific data.
Ingestion	: No specific data.

Delayed and immediate effects and also chronic effects from short and long term exposure

Short term exposure

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Long term exposure

SDS Title: Regadenoson Injection Safety Data Sheet	SDS Number: SDS-000053	Page Number: Page 11 of 16
Function: Regulatory Affairs	Effective Date: February 24, 2026	Version number: 3.0

Section 11. Toxicological information

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Potential chronic health effects

Conclusion/Summary [Product] : Not available.

General : No known significant effects or critical hazards.

Carcinogenicity : No known significant effects or critical hazards.

Mutagenicity : No known significant effects or critical hazards.

Reproductive toxicity : No known significant effects or critical hazards.

Numerical measures of toxicity

Acute toxicity estimates

Product/ingredient name	Oral (mg/kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapors) (mg/l)	Inhalation (dusts and mists) (mg/l)
propane-1,2-diol	20000	20800	N/A	N/A	N/A
disodium hydrogenorthophosphate	17000	2500	N/A	N/A	N/A
Glycine, N,N'-1,2-ethanediylbis[N-(carboxymethyl)-, sodium salt, hydrate (1:2:2)	2214.37	N/A	N/A	11	N/A
regadenoson	5	5	N/A	0.5	N/A

Section 12. Ecological information

Toxicity

Product/ingredient name

propane-1,2-diol

Result

Acute - LC50 - Fresh water

Crustaceans - Water flea -

Ceriodaphnia dubia

Age: <24 hours

1020 mg/l [48 hours]

Acute - LC50 - Fresh water

Fish - Fathead minnow - *Pimephales*

promelas

Age: ≤7 days

710 mg/l [96 hours]

Acute - EC50 - Fresh water

Algae

24200 mg/l [72 hours]

Effect: Mortality

Effect: Mortality

OECD [Alga, Growth Inhibition Test]

SDS Title: Regadenoson Injection Safety Data Sheet	SDS Number: SDS-000053	Page Number: Page 12 of 16
Function: Regulatory Affairs	Effective Date: February 24, 2026	Version number: 3.0

Section 12. Ecological information

disodium hydrogenorthophosphate

Acute - LC50 - Fresh water

Daphnia - Water flea - *Daphnia magna*
3580 mg/l [48 hours]

Acute - LC50 - Fresh water

Fish - *Oncorhynchus mykiss*
>100 mg/l [96 hours]

Acute - EC50 - Fresh water

Algae - *Desmodesmus subspicatus*
>100 mg/l [72 hours]

Acute - NOEC - Fresh water

Fish - *Oncorhynchus mykiss*
100 mg/l [96 hours]

Acute - NOEC - Fresh water

Algae - *Desmodesmus subspicatus*
>100 mg/l [72 hours]

Acute - NOEC - Fresh water

Daphnia - *Daphnia magna*
>100 mg/l [48 hours]

Chronic - NOEC - Fresh water

Daphnia
25 mg/l [21 days]

Effect: Mortality

OECD [Fish, Acute Toxicity Test]

OECD [Alga, Growth Inhibition Test]

OECD [Fish, Acute Toxicity Test]

OECD [Alga, Growth Inhibition Test]

OECD [Daphnia sp. Acute Immobilization Test and Reproduction Test]

OECD [Daphnia Magna Reproduction Test]

Glycine, N,N'-1,2-ethanediylbis[N-(carboxymethyl)-, sodium salt, hydrate (1:2:2)]

Conclusion/Summary [Product]

: Not available.

Persistence and degradability

Product/ingredient name

propane-1,2-diol

Result

100 mg/l - DOC

98.3% [28 days] - Readily

OECD [Ready Biodegradability - Manometric Respirometry Test]

Conclusion/Summary [Product]

: Not available.

Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
propane-1,2-diol	-	-	Readily

Bioaccumulative potential

Product/ingredient name	LogP _{ow}	BCF	Potential
Water	-1.38	-	Low
propane-1,2-diol	-1.07	-	Low
disodium hydrogenorthophosphate	-5.8	-	Low

Mobility in soil

Soil/Water partition coefficient

: Not available.

SDS Title: Regadenoson Injection Safety Data Sheet	SDS Number: SDS-000053	Page Number: Page 13 of 16
Function: Regulatory Affairs	Effective Date: February 24, 2026	Version number: 3.0

Section 12. Ecological information

Other adverse effects

No known significant effects or critical hazards.

Section 13. Disposal considerations

Disposal methods : The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

Section 14. Transport information

	DOT Classification	IMDG	IATA
UN number	Not regulated.	Not regulated.	Not regulated.
UN proper shipping name	-	-	-
Transport hazard class(es)	-	-	-
Packing group	-	-	-
Environmental hazards	No.	No.	No.

Additional information

Special precautions for user : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

Transport in bulk according to IMO instruments : Not available.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Regadenoson Injection Safety Data Sheet	SDS Number: SDS-000053	Page Number: Page 14 of 16
Function: Regulatory Affairs	Effective Date: February 24, 2026	Version number: 3.0

Section 15. Regulatory information

U.S. Federal regulations : TSCA 8(a) CDR Exempt/Partial exemption: Not determined
United States inventory (TSCA 8b): All components are active or exempted.
Clean Water Act (CWA) 311: disodium hydrogenorthophosphate

TSCA 12(b) - Chemical export notification

Not applicable.

Clean Air Act Section 112 (b) Hazardous Air Pollutants (HAPs) : Not listed

Clean Air Act Section 602 Class I Substances : Not listed

Clean Air Act Section 602 Class II Substances : Not listed

DEA List I Chemicals (Precursor Chemicals) : Not listed

DEA List II Chemicals (Essential Chemicals) : Not listed

SARA 302/304

Composition/information on ingredients

No products were found.

SARA 304 RQ : Not applicable.

SARA 311/312

Classification : EYE IRRITATION - Category 2B

Composition/information on ingredients

Name	%	Classification
propane-1,2-diol	≥10 - ≤30	EYE IRRITATION - Category 2B
disodium	≥0.1 - ≤1	EYE IRRITATION - Category 2B
hydrogenorthophosphate		
Glycine, N,N'-1,2-ethanediylbis[N-(carboxymethyl)-, sodium salt, hydrate (1:2:2)	≥0.1 - ≤1	ACUTE TOXICITY (inhalation) - Category 4 SPECIFIC TARGET ORGAN TOXICITY (REPEATED EXPOSURE) - Category 2
regadenoson	≤0.1	ACUTE TOXICITY (oral) - Category 2 ACUTE TOXICITY (dermal) - Category 1 ACUTE TOXICITY (inhalation) - Category 2

SARA 313

Not applicable.

State regulations

Massachusetts : None of the components are listed.

New York : None of the components are listed.

New Jersey : The following components are listed: PROPYLENE GLYCOL

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.

SDS Title: Regadenoson Injection Safety Data Sheet	SDS Number: SDS-000053	Page Number: Page 15 of 16
Function: Regulatory Affairs	Effective Date: February 24, 2026	Version number: 3.0

Section 15. Regulatory information

Pennsylvania : The following components are listed: 1,2-PROPANEDIOL

California Prop. 65

This product does not require a Safe Harbor warning under California Prop. 65.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

Section 16. Other information

Hazardous Material Information System (U.S.A.)

Health	/	1
Flammability		0
Physical hazards		0

Caution: HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. Although HMIS® ratings and the associated label are not required on SDSs or products leaving a facility under 29 CFR 1910.1200, the preparer may choose to provide them. HMIS® ratings are to be used with a fully implemented HMIS® program. HMIS® is a registered trademark and service mark of the American Coatings Association, Inc.

The customer is responsible for determining the PPE code for this material. For more information on HMIS® Personal Protective Equipment (PPE) codes, consult the HMIS® Implementation Manual.

National Fire Protection Association (U.S.A.)



Procedure used to derive the classification

Classification	Justification
EYE IRRITATION - Category 2B	Calculation method

History

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Regadenoson Injection Safety Data Sheet	SDS Number: SDS-000053	Page Number: Page 16 of 16
Function: Regulatory Affairs	Effective Date: February 24, 2026	Version number: 3.0

Section 16. Other information

Date of issue/Date of revision	: 02/24/2026
Date of previous issue	: 03/01/2024
Version	: 3.0
Prepared by	: Sphera Solutions
Key to abbreviations	: ATE = Acute Toxicity Estimate BCF = Bioconcentration Factor GHS = Globally Harmonized System of Classification and Labelling of Chemicals IATA = International Air Transport Association IBC = Intermediate Bulk Container IMDG = International Maritime Dangerous Goods IMO = International Maritime Organization LogPow = logarithm of the octanol/water partition coefficient MARPOL = International Convention for the Prevention of Pollution From Ships, 1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution) N/A = Not available SGG = Segregation Group TDG = Transportation of Dangerous Goods UN = United Nations
References	: HCS (U.S.A.)- Hazard Communication Standard International transport regulations

Indicates information that has changed from previously issued version.

Notice to reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.